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Abstract 
Purpose: Adiponectin is an adipokine with anti-inflammatory and cardiovascular-protective 
properties. Existing epidemiological evidence is conflicting on the exact relationship between 
adiponectin and long-term cardiovascular disease (CVD) risk. Our aim was to prospectively 
assess whether circulating adiponectin is associated with long-term incident CVD. Methods: 
A population-based, prospective study in adults (>18 years) without previous CVD history 
(ATTICA study). Circulating total adiponectin levels were measured at baseline (2001-2002) 
in a sub-sample (n=531; women/men: 222/309; age: 40±11 years) of the ATTICA cohort and 
complete 10-year follow-up data were available in 366 of these participants (women/men: 
154/212; age: 40±12 years). Results: After adjusting for multiple factors, including age, sex, 
body mass index, waist circumference, smoking, physical activity, Mediterranean diet 
adherence, hypertension, diabetes and hypercholesterolemia, our logistic regression analysis 
indicates that an increase in circulating total adiponectin levels by 1 unit was associated with 
36% lower CVD risk (relative risk [RR]: 0.64, 95% confidence interval [CI]: 0.42-0.96; 
p=0.03). Further adjusting for interleukin-6 plasma levels had no significant impact (RR: 
0.60, 95% CI: 0.38-0.94; p=0.03), while additional adjustment for circulating C-reactive 
protein (CRP) modestly attenuated this association (RR: 0.63, 95% CI: 0.40-0.99; p=0.046). 
Conclusions: In our study elevated circulating total adiponectin levels were associated with 
lower 10-year CVD risk in adults without previous CVD, independently of other established 
CVD risk factors. This association appeared to be modestly attenuated by CRP, yet was not 
mediated by interleukin-6 which is the main endocrine/circulating pro-inflammatory 
cytokine.  
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Introduction 
Adipose tissue secretes in the circulation multiple proteins and factors, collectively 
termed as adipokines [1, 2]. Circulating adipokines exert various effects on target 
tissues/organs, thus regulating energy homeostasis, metabolism, insulin sensitivity and 
cardiovascular functions [3, 4]. Adiponectin (initially reported as Acrp30, AdipoQ, apM1 and 
GBP28) is a secretory protein encoded by the ADIPOQ gene and is synthesized/secreted 
almost exclusively by adipocytes, constituting one of the most abundant circulating 
adipokines (approximately 0.01% of the total plasma protein) [5-7]. 
Compiling experimental evidence has shown that adiponectin plays a pleiotropic 
protective role, exhibiting unique anti-inflammatory, insulin-sensitizing, anti-atherogenic and 
cardiovascular-protective properties [4-7]. Notably, in contrast to most other adipokines, 
adiponectin secretion decreases with increasing adiposity [2-7]. As such, the chronic, low-
grade, systemic inflammation, which is caused by increased adiposity and is associated with 
cardiovascular disease (CVD), is characterized not only by increased circulating pro-
inflammatory biomarkers, such as C-reactive protein (CRP) [8], and interleukin-6 (IL-6) [9], 
but also by lower adiponectin plasma levels [5-7]. 
Despite the strong experimental evidence supporting the protective cardio-metabolic 
role of adiponectin, the epidemiological data on the exact relationship between adiponectin 
and long-term CVD risk are inconsistent and conflicting [10]. Indeed, in 2004, Pischon et al. 
showed that high plasma adiponectin levels were associated with significantly lower 
myocardial infarction risk in middle-aged, CVD-free men of the Health Professionals Follow-
up Study over a 6-year follow-up period [11]. However, other prospective studies have failed 
to identify a strong, independent association between circulating adiponectin and coronary 
heart disease (CHD) [12]. Moreover, data from studies in elderly participants or patients with 
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CHD or heart failure have reported a paradoxical positive association between increasing 
adiponectin plasma levels and mortality [10, 13-15].  
It becomes evident that long-term prospective studies are still needed in this field. 
Moreover, the available epidemiological data on this association from prospective cohorts in 
Mediterranean countries are rather limited. With the aforementioned in mind, the aim of the 
present work was to prospectively assess whether circulating adiponectin levels are 
associated with long-term CVD risk in Greek adults from the general population without 
previous CVD. 
 
Materials and Methods 
Study sample 
The ATTICA study is a population-based, prospective survey conducted in the Attica 
region of Greece. The detailed ATTICA study design has been previously described in the 
initial methodology paper [16]. Briefly, 3042 free-living adults (> 18 years old; women/men: 
1528/1514) without previous CVD history were recruited during 2001-2002 through a multi-
stage, random sampling protocol that selected one participant per household. Comprehensive 
baseline assessments, including a physical examination and measurements of key 
biochemical parameters, were performed in all study participants. To address the research 
question of the present work, in a random sub-sample of 531 study participants (women/men: 
222/309; age: 40±11 years) we additionally measured circulating total adiponectin levels. No 
significant differences were observed between the sub-sample of the present study and the 
total study population regarding the distributions of age, gender, physical activity status, 
smoking and dietary habits (all p-values >0.30). The ATTICA study protocol was approved 
by our Institutional Ethics Committee and the study was conducted according to the World 
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Medical Association Declaration of Helsinki. Informed consent was obtained from all 
individual participants included in the study. 
Baseline study assessments 
The baseline study data included demographic characteristics (e.g. age, sex and years 
of education), personal/family history of CVD, hypertension, hypercholesterolemia and 
diabetes, as well as detailed information on dietary and key lifestyle habits (e.g. smoking and 
physical activity), as previously described [16]. Briefly, the dietary evaluation for all study 
participants was performed using a validated semi-quantitative food-frequency questionnaire, 
i.e. the EPIC-Greek questionnaire [17], which was kindly provided by the Unit of Nutrition 
of Athens Medical School, while adherence to the Mediterranean diet was also assessed 
through the MedDietScore (range 0-55; higher score values indicate better adherence) [18]. 
Furthermore, the International Physical Activity Questionnaire (IPAQ) was utilized, as an 
index of weekly energy expenditure, to assess the physical activity level of study participants 
(according to the IPAQ participants were classified as inactive, minimally active and healthy 
active) [19]. Moreover, in the context of this study, current smokers were defined as those 
smoking at least one cigarette per day, while ex-smokers as those who had stopped smoking 
for at least one year prior to study enrollment. Pack-years of smoking were also calculated as 
the product of average cigarettes smoked per day by the years of smoking.  
Anthropometric parameters were measured for all participants, including height which 
was measured to the nearest 0.5 centimeter (cm) with a right-angles triangle resting of the 
participant’s scalp and against the wall (participant without shoes and in the upright position 
with the back square against the measuring wall tape); weight (kilograms; kg) which was 
measured with a lever balance (participant in light undergarments and without shoes); and 
waist circumference (cm) which was measured with an inelastic measuring tape at the 
minimum circumference between the superior iliac crest and the lower margin of the last rib 
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(participant in the upright position and at the end of normal expiration). For each participant, 
the body mass index (BMI) was also calculated as body weight in kilograms divided by the 
square of the height in meters (kg/m2). Although useful to avoid overestimating BMI in 
subjects older than 65 years, no particular formulas were adopted for height estimation in 
study participants over 65 years old. Resting arterial blood pressure (BP; mean of three 
recordings) in a sitting position was also measured for each participant, and participants with 
average BP ≥140/90 mmHg [or on antihypertensive medication(s)] were classified as 
hypertensive. Blood samples were collected from each participant at 8-10 am, following 10-
12 hours of overnight fasting (no food and alcohol intake with the exception of water). 
Accordingly, serum and plasma samples were prepared, aliquoted and stored at -80oC until 
assayed. Total cholesterol, HDL-cholesterol and triglyceride levels were measured using a 
chromatographic enzymatic method in a Technicon automatic analyser RA-1000 (Dade 
Behring, Marburg, Germany). LDL-cholesterol was calculated using the Friedewald formula. 
Hypercholesterolemia was defined as total cholesterol levels >200 mg/dl (or use of lipid-
lowering medications). Fasting blood glucose plasma levels were measured with a Beckman 
glucose analyzer (Beckman Instruments, Fullerton, CA, USA) and participants with levels 
>125 mg/dl [or on antidiabetic medication(s)] were classified as having diabetes. For the 
purposes of this study, measurements were also performed for high sensitivity CRP plasma 
levels by particle-enhanced immunonephelometry [N Latex; Dade-Behring Marburg GmbH, 
Marburg, Germany; intra- and inter-assay coefficients of variation (CV): <5%], as well as for 
total adiponectin and high sensitivity IL-6 plasma levels by enzyme-linked immunosorbent 
assays (R&D systems Inc, Minneapolis, Minnesota; intra- and inter-assay CV for both assays: 
<10%), according to the manufacturer’s protocols.  
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Finally, according to the results of the above baseline assessments, the study 
participants were also classified based on the presence or absence of metabolic syndrome at 
baseline according to the International Diabetes Federation (IDF) criteria/definition [20]. 
ATTICA study 10-year follow-up (2002-2012) and cardiovascular disease incidence  
The ATTICA study 10-year follow-up was performed during 2011-2012 (median 
follow-up duration: 8.41 years), as previously described [21]. Data regarding the CVD health 
status of each study participant included development of: (a) myocardial infarction, angina 
pectoris, other identified forms of ischemia or coronary revascularization (i.e. coronary artery 
bypass surgery and percutaneous coronary intervention); (b) heart failure and chronic 
arrhythmias; and (c) stroke. Medical records and hospital data were obtained to confirm the 
CVD status of participants and the adjudication was performed by trained study physicians 
following the International Statistical Classification of Diseases and Related Health Problems 
10th Revision (ICD10). For participants who died during the study follow-up period, the 
relevant information was acquired from death certificates and relatives. In the context of the 
present study, complete and clinically accurate data regarding the CVD status during the 10-
year study follow-up were obtained for 366 participants with measured baseline total 
adiponectin plasma levels (Table 1). Thus, herein we present the analyses of the adiponectin 
data from this working sub-sample in relation to the documented 10-year incidence of 
fatal/non-fatal CVD. 
Statistical analysis 
Continuous variables are presented as mean values ± standard deviation (SD), and 
categorical variables as frequencies. Normality assumption was assessed via P-P plots. 
Associations between categorical variables were tested using the chi-square test, while 
between continuous variables using Pearson r or Spearman’s rho coefficients for normally 
distributed and skewed variables, respectively. Comparisons of mean values of normally 
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distributed variables between the study participants who developed CVD and the CVD-free 
participants were performed using Student’s t-test, after controlling for equality of variances 
using the Levene’s test. Comparisons of continuous variables without normal distribution 
were performed using the non-parametric Mann-Whitney U-test. Logistic regression models 
were applied to estimate the relative risk of CVD during the 10-year follow up in relation to 
baseline circulating adiponectin levels, including adjustments for multiple confounding 
factors, namely age, sex, BMI, waist circumference, smoking, physical activity level, 
Mediterranean diet adherence, hypertension, diabetes, hypercholesterolemia and key 
circulating pro-inflammatory biomarkers (i.e., IL-6 and CRP). The results of logistic 
regression models are presented as odds ratios (OR) and 95% confidence intervals (CI). 
Survival analysis using Cox Proportional Hazards models was also applied, showing similar 
findings (data not shown in text), but the results from logistic regression were preferred to be 
presented because they showed more robust statistical estimators. All reported p values are 
based on two-sided tests and the corresponding 95% CI. The Statistical Package for Social 
Sciences (SPSS) version 22 (SPSS Inc, Chicago, IL, U.S.A.) was used for all statistical 
analyses. 
 
Results 
Baseline characteristics and 10-year CVD incidence  
The key baseline characteristics of the study participants are summarized in Table 1. 
During the 10-year study follow-up, 27 of the 366 (7.4%) participants with complete follow-
up data and measured baseline adiponectin plasma levels had developed CVD; of these 
subjects 81% were men and 19% women (p for gender difference: 0.01; Table 1). Compared 
to participants who remained CVD-free, the group of participants who developed CVD 
during the 10-year study follow-up consisted mainly of older men, and had more pack-years 
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of smoking and higher baseline BMI and waist circumference values (all p values <0.05; 
Table 1). This group further exhibited at baseline higher incidence of the various metabolic 
syndrome components (i.e., obesity, hypercholesterolemia, hypertension and diabetes) and 
higher incidence of the metabolic syndrome as defined by the IDF criteria, as well as worse 
fasting glycemic and lipidemic profiles and lower adherence to the Mediterranean diet (i.e. 
lower MedDietScore) (all p values <0.05; Table 1).  
In addition, participants who developed CVD during the study follow-up had 
significantly lower baseline total adiponectin plasma levels compared to those who remained 
CVD-free (2.8±1.1 vs. 4.0±1.9 μg/ml, respectively; p <0.001). Finally, these participants also 
had an enhanced pro-inflammatory profile at baseline, as indicated by the significantly higher 
circulating levels of both IL-6 (p <0.001) and CRP (p=0.02), compared to participants 
without CVD during the 10-year study follow-up (Table 1). 
Baseline associations between circulating adiponectin and key study variables   
Table 2 presents the correlations between the baseline total adiponectin plasma levels 
and selected key baseline variables in the study participants with complete 10-year follow-up 
and measured baseline total adiponectin plasma levels (N=366) based on Spearman's rank 
correlation coefficient tests. Circulating adiponectin exhibited significant negative 
correlations with BMI, waist circumference, triglycerides, IL-6 and CRP levels (all p values 
<0.001; Table 2), as well as with LDL-cholesterol and fasting glucose plasma levels 
(p=0.011 and p=0.002 respectively; Table 2). On the other hand, significant positive 
correlations were identified between circulating adiponectin and both the MedDietScore and 
HDL-cholesterol levels (both p values <0.001; Table 2). 
Baseline circulating adiponectin levels and 10-year CVD incidence 
The results of the multi-adjusted logistic regression models applied to assess the 
likelihood (Odds ratio; 95% CI) for the development of CVD during the 10-year study 
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follow-up period in relation to the baseline circulating adiponectin levels are presented in 
Table 3. In the context of this study, after adjusting for age, sex, BMI and waist 
circumference, we found that an increase in circulating adiponectin levels by 1 unit was 
associated with reduced likelihood of CVD by 38% (OR: 0.62, 95% CI: 0.42-0.91; Model 1; 
Table 3). This association remained unaffected by additional adjustments for other known 
CVD-risk related factors, including current smoking (pack-years of smoking were also 
included in the model to incorporate lifelong smoking habit, without any alterations in the 
results), physical activity (defined as reporting physical activities on the IPAQ) and 
Mediterranean diet adherence (Model 2), as well as for hypertension, diabetes and 
hypercholesterolemia (Model 3). Further adjusting for IL-6 plasma levels did not 
substantively affect this relationship, which was modestly attenuated by additional 
adjustment for circulating CRP (Model 4 and Model 5, respectively; Table 3).   
 
Discussion 
Our study presents long-term, prospective data showing that circulating adiponectin 
holds a significant inverse association with the 10-year CVD incidence in adults from the 
Greek general population without previous CVD, independently of several other established 
CVD risk factors. Indeed, in the context of the ATTICA study, this inverse association 
remained significant even after taking into account a range of factors related to CVD risk, 
including age, sex, BMI, waist circumference, smoking, physical activity, Mediterranean diet 
adherence, hypertension, diabetes and hypercholesterolemia. As such, this multi-adjusted 
logistic regression analysis showed that in our study sample an increment of 1 unit in 
circulating total adiponectin levels was associated with 36% lower CVD risk. Moreover, this 
association persisted and was essentially unaffected even after further adjustment for IL-6 
plasma levels, while it was modestly attenuated by the additional adjustment for circulating 
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CRP. This suggest that the mechanisms linking adiponectin to lower long-term CVD risk in 
our study population extend beyond the underlying low-grade inflammation, as expressed by 
these two key pro-inflammatory biomarkers. 
 Our study findings agree with previous epidemiological data indicating a protective 
association between circulating adiponectin and development of CVD [11, 22-31]. Following 
the initial study by Pischon et al. in 2004 which showed that higher plasma adiponectin levels 
were independently associated with lower risk of subsequent CHD in middle-aged CVD-free 
men, a number of subsequent studies have documented similar, at least to some extent, 
findings in various cohorts [22-29]. Furthermore, meta-analysis data from prospective studies 
with a follow-up period ranging from 4 to 20 years (8 nested case-control and 4 cohort 
studies; total of 14960 participants and 4132 incident CHD events) have also showed that 
higher circulating total adiponectin levels were independently associated with lower CHD 
risk in men and women [30]. Similarly, a CVD-protective effect of adiponectin was also 
noted in a meta-analysis of 17 case-control studies in Han Chinese subjects, showing that low 
total adiponectin circulating levels increased the risk of a first CVD event in the Han Chinese 
population [31].  
This inverse association between circulating adiponectin and CVD can be attributed 
to a spectrum of adiponectin-induced anti-inflammatory, anti-atherogenic and cardiovascular-
protective effects which can directly impact on endothelial function, atherosclerosis and 
cardiomyocytes [4-7, 32-34]. As such, anti-inflammatory adiponectin effects appear to play a 
key role against endothelial dysfunction and atherogenesis by inhibiting the pro-inflammatory 
cascade in endothelial cells [34-36]. Moreover, in these cells adiponectin can also suppress 
the excess production of reactive oxygen species induced by high-glucose conditions or 
oxidized-LDL, thus protecting the vasculature in T2DM [37]. Notably, adiponectin can 
further exert vasodilator actions by directly stimulating nitric oxide production in endothelial 
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cells [38]. In addition, adiponectin may protect against the activation of the endothelial 
adhesion molecular cascade which facilitates the entry of macrophages into the vascular wall 
[39], and also suppress the macrophage to foam cell transformation process [40]. Finally, 
adiponectin has been shown to exert direct cardio-protective effects against ischemic 
myocardial injury, heart failure and cardiac hypertrophy [4, 32-34, 41-43]. Indeed, 
adiponectin can protect against myocardial ischemia/reperfusion injury through signaling 
pathways involving both anti-inflammatory and anti-apoptotic actions [42, 43]. Interestingly, 
based on animal studies exploring cardiac remodeling after myocardial infarction, 
adiponectin may protect against systolic dysfunction following myocardial infarction by 
suppressing interstitial fibrosis and cardiac hypertrophy [44]. 
Despite the aforementioned prospective studies and the mounting experimental 
evidence supporting a direct protective role of circulating adiponectin in CVD, we must 
highlight that there is also a significant body of epidemiological data from studies that have 
found either a weaker than expected association between adiponectin plasma levels and CVD 
or no association at all [12, 45-55]. Furthermore, there are also meta-analyses of prospective 
studies reporting lack of a direct association between circulating adiponectin and CHD or 
stroke [12, 55-57]. This inconsistency and the conflicting findings in the literature can be 
attributed, at least in part, to differences between these studies in the design, studied 
population, follow-up duration and methodology (e.g. storing of samples and assays for 
adiponectin measurement), as well as to the various degrees of adjustment for confounding 
factors. For example, smoking is shown to influence the links between pro-inflammatory 
processes, metabolic syndrome and CVD [58], as well as circulating adiponectin levels [59-
61], thus adjustments for smoking habits are required when exploring these associations. 
However, it appears that additional factors implicated in the complex role of adiponectin in 
health and disease states are also responsible for the conflicting epidemiological data (e.g. 
 13 
 
circulating adiponectin forms, expression/role of adiponectin receptors, and regulation of 
adiponectin secretion/actions). 
Of note, adiponectin undergoes post-translational modifications within adipocytes, 
resulting in multimerization [62, 63]. As such, adiponectin is secreted as oligomers of trimers 
which circulate as low molecular weight (LMW: trimers or alternatively both trimers and 
hexamers), medium molecular weight (MMW: hexamers) and high molecular weight 
multimers (HMW: 18- to 36-mers) [3, 62, 63]. The latter predominates in plasma and appears 
to be more metabolically active [62, 63]. Thus, in addition to differences regarding the assays 
used to measure adiponectin, measurement of different forms of circulating adiponectin (total 
or HMW) in various studies may also contribute to the noted inconsistency in reported 
findings.  
Moreover, emerging evidence indicates that the adiponectin receptors further 
influence the circulating levels and role of adiponectin, particularly in relation to CVD [10, 
32, 64, 65]. Adiponectin acts by binding to AdipoR1 (expressed ubiquitously; highest 
expression in skeletal muscle), AdipoR2 (expressed predominantly in the liver), and T-
cadherin (a glycosylphosphatidylinositol-anchored extracellular protein without an 
intracellular domain, highly expressed in the heart, skeletal muscle and in endothelial and 
vascular smooth muscle cells) [32, 64, 65]. Both AdipoR1 and AdipoR2 are seven-
transmembrane receptors and are also expressed in endothelial and vascular smooth muscle 
cells, as well as in the heart where AdipoR1 has relatively greater expression than AdipoR2 
[32, 64]. Notably, T-cadherin is markedly expressed in endothelial and smooth muscle cells 
at sites of vascular injury and exhibits affinity only for the hexameric and HMW adiponectin 
forms [65]. As such, these adiponectin forms interact with T-cadherin and are abundantly 
present on vascular and muscle tissue surfaces where T-cadherin is highly expressed, forming 
a local reservoir [32, 64, 66]. This interaction is considered significant for the cardio-
 14 
 
protective adiponectin effects and for the role of this adipokine in atherosclerosis [10, 32, 64, 
66]. However, the exact mechanism(s) linking these receptors to the effects of adiponectin in 
the context of CVD remain to be clarified. 
Notably, factors relating to the regulation of adiponectin synthesis/secretion, the 
adiponectin forms, and the adiponectin receptors may also be implicated in gender-specific 
differences noted in the relationship between circulating adiponectin and cardiometabolic 
complications [11, 22-24, 46, 49, 67]. Indeed, men appear to exhibit lower adiponectin 
plasma levels, potentially due to suppression by androgens [68]. However, women may also 
have lower circulating adiponectin levels after adjusting for body composition [69]. The latter 
indicates that the higher adiponectin plasma levels in women can be attributed to a more 
favorable body composition profile with less visceral/central adiposity [69]. As such, sex and 
body composition parameters should be taken into account when exploring the association of 
circulating adiponectin with CVD. Of note, opposing gender-specific associations between 
circulating HMW adiponectin and circulating T-cadherin levels have been noted in patients 
with stable coronary artery disease [70]. Moreover, different genotypes of adiponectin could 
be associated with higher CVD risk in a gender-specific way, since data suggest that the C/C 
carriers of the rs266729 SNP of adiponectin may have increased CVD mortality risk 
compared to the C/G or G/G carriers in women, but not in men [71]. Overall, whether 
gender-specific associations of circulating adiponectin with cardiometabolic complications 
involve effects of sex hormones and/or sex-linked genes is not fully clarified yet and requires 
further research. 
Finally, the so-called “adiponectin paradox” may also partly explain the conflicting 
evidence on the relationship between circulating adiponectin and CVD [10]. This paradox is 
noted mainly in older individuals and/or in certain patient groups (e.g. in patients with pre-
existing CHD, chronic heart failure or kidney disease) [10]. Indeed, studies in such 
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populations have shown a positive association between high adiponectin plasma levels and 
increased mortality [10, 13-15]. This may be attributed to different factors which are 
considered to play a role in the relationship of circulating adiponectin with CVD in healthy 
subjects and in certain disease states [10]. According to this hypothesis, in healthy young and 
middle-aged adults the inverse association between circulating adiponectin and CVD is 
driven by increased adiposity (particularly central adiposity) and its pathophysiologic 
consequences (e.g. obesity-related low-grade inflammation) [10]. On the other hand, factors 
relating to cachexia, involuntary weight loss, and sarcopenia are considered to contribute to 
increased secretion of adiponectin in older individuals and in certain chronic diseases [10]. 
These factors may partly account for the observed link between high adiponectin plasma 
levels and increased overall and CVD mortality in such populations [10]. In addition, other 
mechanisms which can also cause increased circulating adiponectin levels in these 
populations appear to include: ineffective compensatory up-regulation of adiponectin 
synthesis; decreased adiponectin signaling efficacy (biological resistance); decreased renal 
elimination of circulating adiponectin; altered expression of adiponectin receptors (e.g. of T-
cadherin); and stimulated adiponectin secretion by certain CVD-related factors (e.g. by 
increased levels of natriuretic peptides) [10]. Moreover, adiponectin can be also produced by 
cardiomyocytes, myocytes and endothelial cells, and this non-adipose-derived adiponectin 
may also play a role in CVD [3, 10]. It becomes evident that multiple factors, alone or in 
synergy, may significantly influence the association of circulating adiponectin with CVD 
and, hence, should be taken into account when interpreting the findings of studies in this 
field.  
In this context, it is also noteworthy that “paradoxical hyperadiponectinemia” has also 
been found in certain obese individuals who are considered metabolically healthy (i.e., 
individuals with BMI over 30 kg/m2 who are without obesity-related metabolic 
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complications, such as T2DM, hypertension and dyslipidemia) [72-77]. These metabolically 
healthy obese subjects may exhibit paradoxically high adiponectin plasma levels despite the 
presence of obesity which is often long-standing and even severe/morbid [72-77]. Indeed, 
Aguilar-Salinas et al. have shown that 20% of obese adults (age range: 18-70 years) with 
BMI over 40 kg/m2 have total adiponectin plasma levels higher than the median level of 
subjects with normal BMI [77]. Moreover, this study showed that total adiponectin plasma 
levels which were paradoxically high over certain thresholds had a positive association with 
the metabolically healthy obese phenotype, even after controlling for age, waist 
circumference and fasting insulin levels [77]. Similar findings have been also reported in 
obese adolescent girls [75, 76]. To what extent, in which specific patient groups (e.g. in 
which ethnic or age groups) and via which underlying mechanisms (e.g. links between 
adiponectin and the role of peripheral adiposity) this paradoxical hyperadiponectinemia may 
have a protective role against obesity-related cardiometabolic complications remains to be 
further elucidated [72-77]. 
Strengths and limitations 
The present work has several strengths since the association between circulating 
adiponectin and CVD incidence was studied in the context of a prospective study with a long 
(10-year) follow-up period that focused specifically in adults from the general population 
without CVD history. Such epidemiological data are sparse from Mediterranean countries. 
Indeed, this is the first long-term, prospective study on CVD epidemiology in Greece, with a 
cohort which is representative of the urban Greek population (participants living in the 
greater Athens metropolitan area, i.e. an urban region, reflecting almost 70% of the total 
Greek population). Furthermore, our study protocol involved assessments of multiple factors 
from all aspects of CVD risk determinants, including socio-demographic, lifestyle, clinical 
and biochemical variables.  
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Despite these strengths, it is also important to acknowledge certain study limitations. 
As such, the relatively smaller sub-group of the ATTICA study participants with measured 
baseline circulating adiponectin levels could be considered a limitation of the present work. 
However, this sub-sample was representative of the total study’s cohort without significant 
differences in the distributions of key factors. The low incidence of CVD noted in this study 
could be another limitation of the present analysis, but this was mainly due to the ATTICA 
study sampling scheme (i.e. enrolling participants from all age groups, representative to the 
total Greek population and without prior CVD); but this could be also viewed as a relative 
advantage, since it may reflect more precisely the true effect size of the studied factors on 
development of CVD in the general population compared to other studies that enrolled 
mainly participants of older age and/or participants with pre-existing CVD. Finally, based on 
our study protocol, we measured total levels of circulating adiponectin without selectively 
measuring HMW adiponectin plasma levels. 
Conclusion 
Our study shows that elevated circulating total adiponectin levels are independently 
associated with lower 10-year CVD risk in adults without previous CVD. This association 
appears to be modestly attenuated by circulating CRP levels, but it was not mediated by IL-6 
which is the main endocrine/circulating pro-inflammatory cytokine. Our present findings add 
to the body of existing evidence on the relationship between total adiponectin plasma levels 
and incident CVD, and offer new data for a population that has been under-represented in 
long-term cardiovascular epidemiology studies. 
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Table 1. Selected key baseline characteristics for the total study sample (N=531) and for all participants with complete 
10-year follow-up and measured baseline total adiponectin plasma levels (N=366) based on the development of fatal 
or non-fatal cardiovascular disease (CVD) during the study follow-up period. 
 Total study 
sample 
Study participants with confirmed CVD status at 
the 10-year follow-up 
 
Baseline characteristics (N=531) All follow-up 
(N=366) 
CVD-free 
(N=339) 
Fatal/non-fatal CVD 
(N=27) 
P 
Age (years) 40±11 40±12 39±11 55±9 <0.001
Gender, % male 58 58 56 81 0.01 
Education (years) 12.4±3.6 12.4±3.6 12.5±3.5 11.3±4.3 0.23 
BMI (kg/m2) 25.9±4.4 26.1±4.5 25.9±4.5 29.1±4.1 <0.001
Waist circumference (cm) 89±16 90±16 89±15 102±13 <0.001
Current smokers (% Yes) 40 41 41 35 0.03 
Ex-smokers (%Yes) 18 17 15 43 0.02 
Years stopped smoking 9.8±8.1 10.1±9.9 9.5±8.2 12.2±11.2 0.077 
Pack-years of smoking 496±501 501±500 441±426 760±704 <0.001
Physical activity status* (% Yes) 38 40 40 33 0.47 
Minimally active (% Yes) 25 26 26 23  
HEPA active (% Yes) 13 14 14 10  
MedDietScore (range: 0-55) 27±6 27±5 27±6 23±5 <0.001
Obesity (% Yes) 17 18 17 33 0.04 
Hypertension (% Yes) 26 29 26 59 <0.001
Diabetes (% Yes) 3 3 2 19 <0.001
Hypercholesterolemia (% Yes) 37 40 37 78 <0.001
Metabolic Syndrome** (% Yes) 45 47 45 70 0.01 
Fasting Glucose (mg/dl) 89±20 90±19 89±17 102±31 0.01 
Total Cholesterol (mg/dl) 189±37 191±38 188±37 220±41 <0.001
Triglycerides (mg/dl) 107±72 108±67 104±64 165±78 <0.001
HDL cholesterol (mg/dl) 48±14 48±13 49±13 40±13 <0.001
LDL cholesterol (mg/dl) 120±35 121±35 118±34 147±39 <0.001
Adiponectin (μg/ml) 4.0±2.0 3.9±1.9 4.0±1.9 2.8±1.1 <0.001
IL-6 (pg/ml) 1.4±0.3 1.4±0.3 1.4±0.4 1.6±0.2 <0.001
CRP (mg/L) 1.8±2.1 1.8±2.2 1.7±2.1 2.5±2.1 0.02 
Data presented as means ± standard deviation for continuous variables, and as frequencies for categorical variables. P 
values for comparisons between CVD-free participants and those with confirmed CVD at the 10-year follow-up 
derived using the Mann-Whitney test for continuous variables and the chi-square test for categorical variables. 
*: Physical activity status: physically active participants categorized as minimally active and healthy enhancing 
physical active (HEPA) based on the International Physical Activity Questionnaire (IPAQ) [19]. 
**: Metabolic syndrome defined based on the International Diabetes Federation (IDF) criteria/definition [20].  
CVD: cardiovascular disease; BMI: body mass index; WC: waist circumference; MedDietScore: score evaluating the 
adherence to the Mediterranean diet (higher score values indicate better adherence); IL-6: interleukin 6; CRP: C-
reactive protein 
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Table 2. Correlations between circulating total adiponectin levels and 
selected baseline variables in the participants with complete 10-year 
follow-up and measured baseline adiponectin plasma levels (N=366) 
tested by the Spearman's rank correlation coefficient. 
Baseline characteristics Circulating total adiponectin levels 
r P value 
BMI (kg/m2) -0.336 <0.001 
Waist circumference (cm) -0.389 <0.001 
Fasting Glucose (mg/dl) -0.161   0.002 
Total cholesterol (mg/dl) -0.088   0.096 
Triglycerides (mg/dl) -0.319 <0.001 
LDL cholesterol (mg/dl) -0.136   0.011 
HDL cholesterol (mg/dl) 0.431 <0.001 
MedDietScore (range: 0-55) 0.343 <0.001 
IL-6 (pg/ml) -0.181   0.001 
CRP (mg/L) -0.175   0.001 
Pack-years of smoking  -0.067   0.250 
BMI: body mass index; WC: waist circumference; MedDietScore: score 
evaluating the adherence to the Mediterranean diet (higher score values 
indicate better adherence); IL-6: interleukin 6; CRP: C-reactive protein 
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Table 3. Results from logistic regression analysis models estimating the relative risk 
(Odds ratio; 95% Confidence Intervals) for the development of a cardiovascular disease 
event (outcome) during the 10-year study follow-up period according to the baseline 
circulating total adiponectin levels. 
 10-year risk of a CVD event (outcome) according 
to the baseline circulating adiponectin levels 
Model Odds ratio (95% CI) P value 
1 0.62 (0.42-0.91) 0.01 
2 0.63 (0.43-0.92) 0.02 
3 0.64 (0.42-0.96) 0.03 
4 0.6 (0.38-0.94) 0.03 
5 0.63 (0.4-0.99) 0.046 
Model 1: adjusted for age, sex, body mass index, and waist circumference 
Model 2: Model 1 additionally adjusted for current smoking (pack-years of smoking were also 
included to incorporate lifelong smoking habit, without any significant change in the results), 
physical activity and MedDietScore  
Model 3: Model 2 additionally adjusted for hypertension, diabetes, and hypercholesterolemia 
Model 4: Model 3 additionally adjusted for circulating Interleukin-6 levels 
Model 5: Model 3 additionally adjusted for circulating C-reactive protein levels 
CI: Confidence Intervals; CVD: cardiovascular disease; MedDietScore: score evaluating the 
adherence to the Mediterranean diet (higher score values indicate better adherence) 
 
